Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The […]
Redwood Wealth Management Group LLC acquired a new position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 33,230 shares of the company’s stock, valued at approximately $113,000. Other hedge funds and other […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) CEO Richard A. Paulson sold 3,497 shares of the company’s stock in a transaction dated Tuesday, April 4th. The stock was sold at an average price of $3.97, for a total transaction of $13,883.09. Following the completion of the transaction, the chief executive officer now owns 816,619 shares […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 16,730,000 shares, a decline of 8.7% from the February 28th total of 18,330,000 shares. Based on an average daily volume of 2,760,000 shares, the […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) was the target of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 16,730,000 shares, a decline of 8.7% from the February 28th total of 18,330,000 shares. Based on an average daily trading volume, of 2,760,000 shares, […]